Latest Breaking News On - Patient reported - Page 3 : comparemela.com

Bristol Myers Squibb (NYSE:BMY) today announced that additional data from multiple studies evaluating Zeposia (ozanimod) in ulcerative colitis (UC) were presented at Digestive Disease Week ® (DDW), taking place virtually May 21-23, 2021. These data deepen the understanding of Zeposia and reinforce Bristol Myers Squibb’s commitment to understanding and addressing unmet needs in gastroenterology. Research being shared includes: Safety of Ozanimod in Patients with Moderately to Severely Active Ulcerative Colitis Over Time: Pooled Analysis from Phase 2, Phase 3, and Open-Label Extension Trials Pooled analysis including data from the Phase 2 TOUCHSTONE study, Phase 3 True North study and open-label extension trial. Long-term treatment with

United statesMary beth harlerBristol myers squibbAmerican society for gastrointestinal endoscopyBristol myers squibb companyHealth economicsAmerican gastroenterological associationFibrosis developmentSociety for surgery of the alimentary tractDrug administrationEuropean commissionOutcomes researchExchange commissionEuropean medicines agencyMyers squibbDigestive disease week